Biocon Biologics Ltd (BBL), the biosimilars company and subsidiary of Biocon Ltd, has announced a licence agreement with Regeneron to commercialise Yesafili, a drug used to treat ophthalmological ...

Additionally, Biocon Biologics secured a settlement agreement in Canada with Bayer and Regeneron Pharma for launch of YESAFILI no later than July 1, 2025.

Biocon Biologics has reached a settlement with Regeneron, allowing the launch of Yesafili, its biosimilar eye drug, in the US by the second half of 20 ...

This agreement enables the company to launch in the US in the second half of calendar year 2026 or earlier in certain circumstances ...

Biocon Biologics on Tuesday said it has inked a settlement and licensing pact with Regeneron, paving the way to commercialise its biosimilar product Yesafili in the US.

Biocon share price has gained 1.6% in one month, but the stock has declined 11% on a year-to-date (YTD) basis. Biocon shares have rallied 23% in one year and more than 46% in two years.

Biocon Biologics secures market entry date for Yesafili, an interchangeable biosimilar to Eylea, in US: Our Bureau, Bengaluru Tuesday, April 15, 2025, 11:30 Hrs [IST] Biocon Biolo ...

BENGALURU: Biopharmaceutical company Biocon's share price on Tuesday jumped over 4 per cent after its subsidiary Biocon Biologics Ltd (BBL) announced its settle ...

“This settlement clears the path for Biocon Biologics to be among the first to bring a reliable, high-quality aflibercept biosimilar to patients and healthcare providers in the U.S.,” said Shreehas ...